KalVista Pharmaceuticals (FRA:4XC1) Cyclically Adjusted PS Ratio : (As of Jun. 20, 2024)

View and export this data going back to 2016. Start your Free Trial

What is KalVista Pharmaceuticals Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation

KalVista Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for KalVista Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KalVista Pharmaceuticals Cyclically Adjusted PS Ratio Chart

KalVista Pharmaceuticals Annual Data

Trend

Dec14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Cyclically Adjusted PS Ratio

Get a 7-Day Free Trial

KalVista Pharmaceuticals Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Cyclically Adjusted PS Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of KalVista Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, KalVista Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

KalVista Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, KalVista Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where KalVista Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.

KalVista Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

KalVista Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jan. 2024 is calculated as:

For example, KalVista Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jan. 2024 was:

Adj_RevenuePerShare	=	Revenue per Share	/	CPI of Jan. 2024 (Change)	*	Current CPI (Jan. 2024)
	=	0	/	130.1244	*	130.1244
	=	0.000

Current CPI (Jan. 2024) = 130.1244.

KalVista Pharmaceuticals Quarterly Data

	Revenue per Share	CPI	Adj_RevenuePerShare
201403	0.006	99.695	0.008
201406	0.006	100.560	0.008
201409	0.011	100.428	0.014
201412	0.006	99.070	0.008
201503	0.003	99.621	0.004
201506	0.004	100.684	0.005
201509	0.003	100.392	0.004
201512	0.004	99.792	0.005
201603	0.003	100.470	0.004
201606	0.003	101.688	0.004
201609	0.003	101.861	0.004
201701	0.030	102.456	0.038
201704	0.011	103.167	0.014
201707	0.009	103.278	0.011
201710	0.096	104.070	0.120
201801	0.177	104.578	0.220
201804	0.366	105.708	0.451
201807	0.295	106.324	0.361
201810	0.322	106.695	0.393
201901	0.198	106.200	0.243
201904	0.152	107.818	0.183
201907	0.172	108.250	0.207
201910	0.199	108.577	0.238
202001	0.080	108.841	0.096
202004	0.197	108.173	0.237
202007	0.000	109.318	0.000
202010	0.000	109.861	0.000
202101	0.000	110.364	0.000
202104	0.000	112.673	0.000
202107	0.000	115.183	0.000
202110	0.000	116.696	0.000
202201	0.000	118.619	0.000
202204	0.000	121.978	0.000
202207	0.000	125.002	0.000
202210	0.000	125.734	0.000
202301	0.000	126.223	0.000
202304	0.000	127.992	0.000
202307	0.000	128.974	0.000
202310	0.000	129.810	0.000
202401	0.000	130.124	0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

KalVista Pharmaceuticals (FRA:4XC1) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.

KalVista Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of KalVista Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

KalVista Pharmaceuticals (FRA:4XC1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (FRA:4XC1) » Definitions » Cyclically Adjusted PS Ratio

Comparable Companies

Traded in Other Exchanges

KALV:USA

Address

55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142

Website

https://www.kalvista.com

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.

KalVista Pharmaceuticals (FRA:4XC1) Headlines

No Headlines